Since the first cases of AIDS were reported 30 years ago, HIV remains a difficult target for the research field. Although there is no cure for AIDS, HIV infection can be prevented, however in many countries across the world access to prevention and treatment services is limited. Global leaders have pledged to work towards universal access to HIV prevention and care, so that millions of deaths can be averted.There is much that can be done to reduce the impact of AIDS, beginning with the prevention of HIV transmission.In this sense, the main objective of this proposal is to decrease the virus spread avoiding the infection among women. Diminishing HIV transmission among women is a key step towards undermine the virus presence since it will not be transmitted to the new generation of children and to their partners. AIM-HIV project aims to reduce the transmission of HIV in countries with high incidence through the development of a new effective and low-cost microbicide based on 5-Hydroxytyrosol.For this aim, the proposed Consortium will be composed by an SME company with strong research and development capacities and broad experience in the field of hydroxytyrosol, SEPROX Biotech S.L., and three European research groups with a profound knowledge on HIV and cellular HIV infection and integration: Instituto de Salud Carlos III (ISCIII), Commissariat à l’énergie atomique et aux energies alternatives (CEA) and Università Vita-Salute San Raffaele (USR).The duration of the project will be 30 months, with a total budget of 2,331,804€ and a requested grant of 1,827,081€. The estimated EU contribution going to the SME SEPROX is a 25.3% of the total requested EU contribution for the project as a whole.The Consortium has already contacted with organizations and institutions that have a huge interest in the project´s result and will have an important role for assuring the proper dissemination of the final product which will be widely accessible and manage by women themselves